Check-Cap (NASDAQ:CHEK) Coverage Initiated at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Check-Cap (NASDAQ:CHEKGet Free Report) in a research report issued on Sunday. The brokerage set a “sell” rating on the medical research company’s stock.

Check-Cap Price Performance

Shares of NASDAQ:CHEK opened at $2.17 on Friday. The business’s 50 day moving average is $2.25 and its 200-day moving average is $2.97. Check-Cap has a 1-year low of $1.22 and a 1-year high of $4.63.

Check-Cap (NASDAQ:CHEKGet Free Report) last released its quarterly earnings data on Monday, November 27th. The medical research company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.39. As a group, analysts anticipate that Check-Cap will post -2.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP acquired a new stake in shares of Check-Cap in the 4th quarter valued at $31,000. Susquehanna International Group LLP bought a new position in Check-Cap in the first quarter valued at about $57,000. Citadel Advisors LLC increased its position in Check-Cap by 51.2% in the third quarter. Citadel Advisors LLC now owns 141,319 shares of the medical research company’s stock worth $41,000 after purchasing an additional 47,868 shares during the period. Sabby Management LLC bought a new stake in Check-Cap during the 1st quarter worth about $91,000. Finally, Virtu Financial LLC lifted its position in Check-Cap by 363.4% during the 2nd quarter. Virtu Financial LLC now owns 224,696 shares of the medical research company’s stock valued at $69,000 after purchasing an additional 176,207 shares during the period. Institutional investors own 0.21% of the company’s stock.

Check-Cap Company Profile

(Get Free Report)

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.

Further Reading

Receive News & Ratings for Check-Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap and related companies with MarketBeat.com's FREE daily email newsletter.